Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

ImmunoGen, Inc. (IMGN)

3.96   -0.12 (-2.94%) 03-17 16:00
Open: 4.08 Pre. Close: 4.08
High: 4.1 Low: 3.855
Volume: 4,703,788 Market Cap: 895(M)

Technical analysis

as of: 2023-03-20 7:46:47 AM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 4.91     One year: 5.3
Support: Support1: 3.66    Support2: 3.04
Resistance: Resistance1: 4.2    Resistance2: 4.53
Pivot: 4.07
Moving Average: MA(5): 4.06     MA(20): 4.04
MA(100): 4.8     MA(250): 4.86
MACD: MACD(12,26): -0.1     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 43.9     %D(3): 48.2
RSI: RSI(14): 44.1
52-week: High: 6.63  Low: 3.09
Average Vol(K): 3-Month: 3,533 (K)  10-Days: 3,336 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ IMGN ] has closed above bottom band by 33.6%. Bollinger Bands are 15.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.11 - 4.13 4.13 - 4.15
Low: 3.8 - 3.83 3.83 - 3.85
Close: 3.92 - 3.97 3.97 - 4

Company Description

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Headline News

Fri, 17 Mar 2023
Research Analysts Set Expectations for ImmunoGen, Inc.'s FY2025 ... - MarketBeat

Tue, 14 Mar 2023
Analysts Consensus Recommendation Is "Hold" for ImmunoGen, Inc ... - Best Stocks

Tue, 14 Mar 2023
Analyzing the Price-to-Earnings Ratio of ImmunoGen Inc. (IMGN) - The News Heater

Tue, 07 Mar 2023
ImmunoGen, Inc. (NASDAQ:IMGN) is expected to earn ($0.24) per ... - Best Stocks

Mon, 06 Mar 2023
ImmunoGen, Inc. (NASDAQ:IMGN) Expected to Earn Q1 2023 ... - MarketBeat

Sat, 04 Mar 2023
ImmunoGen, Inc. (NASDAQ:IMGN) to Post FY2025 Earnings of ... - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 226 (M)
Shares Float 203 (M)
% Held by Insiders 0.4 (%)
% Held by Institutions 93 (%)
Shares Short 22,800 (K)
Shares Short P.Month 17,780 (K)

Stock Financials

EPS -0.84
EPS Est Next Qtl -0.24
EPS Est This Year -0.73
EPS Est Next Year -1.38
Book Value (p.s.) 0.68
Profit Margin (%) -205
Operating Margin (%) -203.1
Return on Assets (ttm) -31.6
Return on Equity (ttm) -92.7
Qtrly Rev. Growth 47
Gross Profit (p.s.) -0.47
Sales Per Share 0.48
EBITDA (p.s.) -0.97
Qtrly Earnings Growth 0
Operating Cash Flow -230 (M)
Levered Free Cash Flow -102 (M)

Stock Valuations

PE Ratio -4.72
PEG Ratio 0
Price to Book value 5.73
Price to Sales 8.22
Price to Cash Flow -3.9

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.